Nicole L. Stone - Concepedia

Author

Nicole L. Stone

GlaxoSmithKline (United States)ORCID

Also Known As

A. Stapleton, N Stone, N. L. Stone, N. Stone, N.L. Stone, Nicole L Stone, Nicole L. Stone, Nicole Stone, Soler, Yemmy

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)Cornell University Georgia Cancer Specialists Chinese University of Hong Kong

About

Nicole L. Stone is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.8K
2	Health Sciences	3	3	666
3	Natural Sciences	2	2	516
4	Cell Biology	2	2	516
5	Cellular Physiology	1	1	491

Nicole L. Stone

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura James B. Bussel, Gregory Cheng, Mansoor N. Saleh, New England Journal of Medicine	2007	787
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study Gregory Cheng, Mansoor N. Saleh, Claus Werenberg Marcher, The Lancet ThrombopoiesisThrombosisVenous ThrombosisAutoimmune DiseaseBlood Platelet	2010	574
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial James B. Bussel, Drew Provan, Tahir Shamsi, The Lancet Platelet CountsThrombosisThrombopoiesisBlood PlateletHematology	2009	537
Apoptotic Membrane Blebbing Is Regulated by Myosin Light Chain Phosphorylation Jason C. Mills, Nicole L. Stone, Joseph A. Erhardt, The Journal of Cell Biology ApoptosisKinase InhibitorsCell DeathMolecular BiologyCytoskeleton	1998	491
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, New England Journal of Medicine	2023	255
A Novel Transwell Blood Brain Barrier Model Using Primary Human Cells Nicole L. Stone, Timothy J. England, Saoirse E. O’Sullivan Frontiers in Cellular Neuroscience	2019	229
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial Uwe Platzbecker, Raymond Wong, Amit Verma, The Lancet Haematology Eltrombopag Versus PlaceboThrombosisHematological MalignancyVenous ThrombosisOncology	2015	79
Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP) James B. Bussel, Mansoor N. Saleh, Sandra Y. Vasey, British Journal of Haematology	2012	68
A Novel F Box Protein, NFB42, Is Highly Enriched in Neurons and Induces Growth Arrest Joseph A. Erhardt, Weslia P Hynicka, Angela J. DiBenedetto, Journal of Biological Chemistry	1998	65
A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract Christian Wülfing, J-P. Machiels, Dick J. Richel, Journal of Clinical Oncology Cancer ManagementPathologyPhase Ii StudyTumor BiologyOncology	2005	56

Page 1